Onkos Surgical today said it has launched its new Eleos Proximal Tibia with BioGrip technology.
The implant is designed for use in complex tumor and orthopedic reconstructive procedures. It is touted as the first FDA cleared, 3D printed limb salvage replacement.
“The new Eleos Proximal Tibia with BioGrip offers features that are intended to help address the challenges associated with proximal tibial replacement. Careful consideration went into the design and trajectory of the suture holes which are designed to provide fixation for important soft tissue anatomy,” chief medical officer Steven Gitelis said in a news release. “The BioGrip 3D printed design provides a consistent porous structure on the implant in key anatomical areas to support bone and soft tissue apposition. These elements deliver meaningful enhancements in a procedure that presents many clinical challenges.”
BioGrip and its 3D printed porous structure is set to be leveraged on future innovations of the Eleos Limb Salvage family of products and other personalized implant solutions at Onkos Surgical.
“2020 was an incredibly gratifying year for Onkos Surgical. We launched four new products – our new Eleos Proximal Femoral Replacement, Eleos Proximal Tibia with BioGrip, GenVie Magnesium Bone Scaffold and uDesign on-demand personalized surgical planning – all of which have brought innovation and focused improvements to surgeons and patients,” CEO Patrick Treacy said. Our new US partnership with Integrum AB to distribute the OPRA™ osseointegration device has meant an improved quality of life for amputee patients. We continue to invest heavily in our R&D engine to ensure we maintain a consistent drumbeat of new product introductions that will provide meaningful advancements for our surgeons and the patients they care for.”
“When we started Onkos Surgical, we said we would emphasize key innovation verticals that help surgeons address the clinical challenges related to soft tissue attachment, aseptic loosening and infection management. We remain uniquely positioned and focused on delivering on that promise. 2020 presented us with an opportunity to accelerate our innovation and continue to disrupt the status quo for the benefit of many surgeons and patients,” senior VP of commercial operations Sean Curry said.
